Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
5.50
-0.03 (-0.54%)
At close: Apr 24, 2026, 4:00 PM EDT
5.39
-0.11 (-2.00%)
After-hours: Apr 24, 2026, 5:26 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,309,341
Market Cap
16.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioCardia | 21 |
| IN8bio | 17 |
| Moleculin Biotech | 17 |
| Soligenix | 14 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| CDT Equity | 6 |
| Jupiter Neurosciences | 5 |
CVKD News
- 25 days ago - Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - GlobeNewsWire
- 6 weeks ago - Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 6 weeks ago - Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - GlobeNewsWire
- 7 weeks ago - Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewsWire
- 2 months ago - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - GlobeNewsWire
- 3 months ago - Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit - Transcripts
- 3 months ago - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - GlobeNewsWire
- 4 months ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire